ralinepag
Small moleculeexperimental
Clinical trial activity
6 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Dec 1, 2014 (NCT02279160)
Timeline
Indications
Studied for
- Cardiovascular Diseases · Phase 3
- Connective Tissue Diseases · Phase 3
- Familial Primary Pulmonary Hypertension · Phase 3
- Healthy Volunteers · Phase 1
- Hypertension · Phase 3
- Hypertension, Pulmonary · Phase 3
- Lung Diseases · Phase 3
- Pharmacokinetics · Phase 1
- Pulmonary Arterial Hypertension · Phase 3
- Respiratory Tract Diseases · Phase 3
- Vascular Diseases · Phase 3
Mechanism of action
- Prostanoid IP receptorAGONIST
PTGIR agonist
Chemistry & pharmacology
Loading structure…
SMILES
O=C(O)COC[C@H]1CC[C@H](COC(=O)N(c2ccccc2)c2ccc(Cl)cc2)CC1- Mol. weight
- 431.92 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3301604 ↗
Also known as
- apd811
- apd-811
- apd-811
- ralinepag
- ralinepag
- ralinepag
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04613999 | Phase 1 | Oct 9, 2020 | Everstar Therapeutics Limited, Peking University |
| NCT04084678 | Phase 3 | Dec 15, 2019 | United Therapeutics |
| NCT03683186 | Phase 3 | Sep 30, 2018 | Arena Pharmaceuticals |
| NCT03626688 | Phase 3 | Aug 30, 2018 | Arena Pharmaceuticals |
| NCT02279745 | Phase 2 | Jul 1, 2015 | Arena Pharmaceuticals |
| NCT02279160 | Phase 2 | Dec 1, 2014 | Arena Pharmaceuticals |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Arena Pharmaceuticals | For profit | 4 | 4 | 2 | 2014 |
| Everstar Therapeutics Limited | For profit | 1 | 1 | 1 | 2020 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2020 |
| United Therapeutics | For profit | 1 | 1 | 1 | 2019 |
4 organizations
Page 1 / 1